PV-0208 Immune-related pneumonitis in NSCLC patients treated with ICI: impact of previous thoracic RT

Botticella, Angela; Ibrahim, Toni; Mezquita, Laura; Hendriks, L.; Pavec, Jérôme Le; Ferrara, Roberto; Caramella, Caroline; Champiat, Stéphane; Michot, Jean‐Marie; Lavaud, Pernelle; Gustin, P.; Planchard, David; Gazzah, A.; Marabelle, Aurélien; Deutsch, Éric; Besse, Benjamin; Péchoux, C. Le

doi:10.1016/s0167-8140(19)30628-0

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Together with another retrospective study by the same study group, the overall incidence of checkpoint inhibitor pneumonitis is found to be significantly higher than that was reported in other clinical studies 56 . The retrospective study by Botticella et al also supported that NSCLC patients treated with ICIs and previous curative-intent TRT may be at higher pulmonary risk, where pneumonitis of grade ≥ 3 occurred in 16.7% of the patients on combination therapy and in 2.4% of the patients on ICI monotherapy (P < 0.001) 51 . Possible reasons include increased awareness and pharmacovigilance with irAEs in recent years.…”

Section: Clinical Datamentioning

confidence: 87%

Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy

Gan

Song

et al. 2019

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Part of the Oncology Commons, and the Radiation Medicine Commons This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Radiation Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons.

show abstract

Section: Clinical Datamentioning

confidence: 87%

Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy

Gan

Song

et al. 2019

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

show abstract

“…Botticella et al evaluated the incidence of pneumonia in 318 patients with non-small cell lung cancer who had received previous chest radiotherapy and second-line immunotherapy in a retrospective analysis. The results showed that PD-1 inhibitors significantly increased the risk of pneumonia in patients [89]. KEYNOTE-001 studied the safety of pembrolizumab, a representative PD-1 inhibitor, in the treatment of non-small cell lung cancer patients [90].…”

Section: Pd-1 Inhibitorsmentioning

confidence: 99%

Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy

et al. 2023

View full text Add to dashboard Cite

As one of the common complications of radiotherapy, radiation pneumonia (RP) limits the prognosis of patients. Therefore, better identifying the high-risk factors that lead to RP is essential to effectively prevent its occurrence. However, as lung cancer treatment modalities are being replaced and the era of immunotherapy has arrived, literature that reviews the parameters and mode of radiotherapy, chemotherapy drugs, targeted drugs and current hot immune checkpoint inhibitors related to RP is lacking. This paper summarizes the risk factors for radiation pneumonia by retrieving and analysing previously published literature and the results of large clinical trials. The literature primarily included retrospective analyses, including clinical trials in different periods and a part of the literature review. A systematic literature search of Embase, PubMed, Web of Science, and Clinicaltrials.gov was performed for relevant publications up to 6 Dec. 2022. Search keywords include, but are not limited to, “radiation pneumonia”, “pneumonia”, “risk factors”, “immunotherapy”, etc. The factors related to RP in this paper include physical parameters of radiotherapy, including V5, V20, and MLD; chemoradiotherapy mode and chemotherapy drugs, including paclitaxel and gemcitabine; EGFR-TKI; ALK inhibitors; antiangiogenic drugs; immune drugs and the underlying disease of the patient. We also introduce the possible mechanism of RP. In the future, we hope that this article not only sounds the alarm for clinicians but also helps to identify a method that can effectively intervene and reduce the occurrence of RP, significantly improve the quality of life and prognosis of patients, and more effectively improve the therapeutic effect of radiation therapy.

show abstract

“…Similarly, Botticella assessed the effect of previous chest radiotherapy on the occurrence of pneumonitis after combined therapy in 318 NSCLC patients and found that the incidence of grade ≥3 pneumonitis was significantly higher in patients who received chest radiotherapy than in those who did not (11.1% vs 0.4%, P < 0.01). 99 …”

Section: Pneumonitis Occurring After Radiotherapy Combined With Immun...mentioning

confidence: 99%

“…NSCLC patients and found that the incidence of grade ≥3 pneumonitis was significantly higher in patients who received chest radiotherapy than in those who did not (11.1% vs 0.4%, P < 0.01). 99 There seems to be some difference in the incidence of pneumonitis in NSCLC patients treated with CRT concurrently or with sequential PD-1/PD-L1 inhibitors. Jabbour performed a Phase 1 nonrandomized controlled trial of PD-1 inhibitors combined with radiotherapy and chemotherapy for the treatment of locally advanced non-small cell lung cancer.…”

mentioning

confidence: 99%

Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer

Zhang¹,

Yang²,

Gao³

et al. 2022

CMAR

View full text Add to dashboard Cite

Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%–13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.

show abstract

PV-0208 Immune-related pneumonitis in NSCLC patients treated with ICI: impact of previous thoracic RT

Cited by 4 publications

References 0 publications

Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy

Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy

Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy

Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About